Satralizumab
- Generic Name
- Satralizumab
- Brand Names
- Enspryng
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1535963-91-7
- Unique Ingredient Identifier
- YB18NF020M
- Background
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the cent...
- Indication
Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In Canada, it is also used in adolescent patients for the same indication.
- Associated Conditions
- Neuromyelitis Optica Spectrum Disorders
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath